GARADACIMAB-GXII: 21 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
21
Total FAERS Reports
0
Deaths Reported
3
Hospitalizations
21
As Primary/Secondary Suspect
1
Life-Threatening
Prescription
Status
FDA Application: 761367 ·
First Report: 20240816 · Latest Report: 20250904
What Are the Most Common GARADACIMAB-GXII Side Effects?
#1 Most Reported
Hereditary angioedema
12 reports (57.1%)
#2 Most Reported
Abdominal pain
4 reports (19.0%)
#3 Most Reported
Drug ineffective
3 reports (14.3%)
All GARADACIMAB-GXII Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Hereditary angioedema | 12 | 57.1% | 0 | 0 |
Who Reports GARADACIMAB-GXII Side Effects? Age & Gender Data
Gender: 81.8% female, 18.2% male. Average age: 45.3 years. Most reports from: US. View detailed demographics →
Is GARADACIMAB-GXII Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2024 | 1 | 0 | 0 |
| 2025 | 10 | 0 | 1 |
What Is GARADACIMAB-GXII Used For?
| Indication | Reports |
|---|---|
| Hereditary angioedema | 15 |
| Prophylaxis | 9 |
Official FDA Label for GARADACIMAB-GXII
Official prescribing information from the FDA-approved drug label.